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NOTABLE NOTES
Tumor Necrosis Factor and the Tenacious α
Øystein Grimstad, MD, PhD
Tumor necrosis factor (TNF) is a central cytokine in inflammation and an
important therapeutic target in dermatology. For reasons unknown, TNF
is still referred to as TNF-α in numerous newly published scientific papers,
almost 2 decades after the cytokine was renamed. Of notice, this transgres-
sion is common in biomedical science, not limited to dermatology.
In 1975, Carswell and colleagues1 identified TNF from human serum
as responsible for necrosis in different tumors in mice. Demonstration
of functional and sequential homology of TNF and the previously dis-
covered cytotoxic factor lymphotoxin in 1985 resulted in renaming of
TNF as TNF-α and lymphotoxin as TNF-β.2 These 2 cytokines laid the
foundation for the isolation and identification of the larger family of cy-
tokines, now known as the TNF superfamily. In 1993, a close homo-
logue of lymphotoxin, the lymphotoxin-β, was discovered.3 Subse-
quently, at the Seventh International TNF Congress (May 17-21, 1998;
Hyannis, Massachusetts), the name “TNF-β” was changed to “lympho-
toxin-α.” Concurrently, “TNF-α” became an orphan term with no mean-
ing different from the original term, “TNF,” which was reinstated as of-
ficial name of the cytokine.
Ideally, protein names and symbols would be identical to those used
for the gene. The official symbol of the cytokine gene by the HUGO Gene
Nomenclature Committee is TNF. Also the international Universal Pro-
tein Resource (UniProt) recommends tumor necrosis factor as the name
of the protein. A consistent use of approved nomenclature will facili-
tate data retrieval using unique approved symbols as search terms in cen-
tral databases such as PubMed, GenBank, and OMIM. This warrants aban-
doning the term “TNF-α” when referring to tumor necrosis factor,
probably the most featured signal molecule in dermatology.
Author Affiliation: Department of Dermatology, University Hospital in
North Norway, Tromsø, Norway.
Corresponding Author: Øystein Grimstad, Department of Dermatology,
University Hospital in North Norway, N-9038 Tromsø, Norway
(oystein.grimstad@unn.no).
1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An
endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad
Sci U S A. 1975;72(9):3666-3670.
2. Browning JL, Ngam-ek A, Lawton P, et al. Lymphotoxin beta, a novel
member of the TNF family that forms a heteromeric complex with lymphotoxin
on the cell surface. Cell. 1993;72(6):847-856.
3. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor:
precursor structure, expression and homology to lymphotoxin. Nature. 1984;
312(5996):724-729.
Point-of-Care Treatment Decisions for Hidradenitis Suppurativa Original Investigation Research
jamadermatology.com (Reprinted) JAMA Dermatology May 2016 Volume 152, Number 5 557
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/derm/935291/ by a Norwegian Institute of Public Health User  on 03/01/2017
